BMY Stock Overview
Bristol-Myers Squibb Company develops, licenses, manufactures, and markets biopharmaceutical products worldwide.
Bristol-Myers Squibb Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$54.64|
|52 Week High||US$69.75|
|52 Week Low||US$54.60|
|1 Month Change||-6.44%|
|3 Month Change||-18.28%|
|1 Year Change||-12.44%|
|3 Year Change||2.55%|
|5 Year Change||-1.64%|
|Change since IPO||283.44%|
Recent News & Updates
Bristol-Myers: Value Time Again
Bristol-Myers has seen a relatively uneventful 2021 after the Celgene and MyoKardia deal. Leverage has rapidly come under control. Bristol-Myers needs some further success on the topline sales front, amidst some upcoming expirations. The situation is very manageable amidst a non-demanding valuation. I am happily adding to my position here.
Bristol Myers Squibb: 5 Reasons To Buy The Current Dip, And 1 Caveat
Bristol Myers Squibb is the pharma with the share price that refuses to budge. Over the past five years, shares are up just 2%. Substantial investment in new assets and a strong pipeline helped shares grow nearly 20% in the first 9m of this year, before the recent slide back to $58. Everything seems to be in place for the pharma to drive some strong growth in 2022 however and finally buck the stagnant growth trend. I highlight five key strengths in the post below - I believe the intrinsic value of BMY shares could be as high as $100. The only caveat is the number of false dawns the company has experienced - will this time be different? I believe so.
Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|BMY||US Pharmaceuticals||US Market|
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 15.2% over the past year.
Return vs Market: BMY underperformed the US Market which returned 23.3% over the past year.
|BMY Average Weekly Movement||2.4%|
|Pharmaceuticals Industry Average Movement||9.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.0%|
|10% least volatile stocks in US Market||2.3%|
Stable Share Price: BMY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: BMY's weekly volatility (2%) has been stable over the past year.
About the Company
Bristol-Myers Squibb Company develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Bristol-Myers Squibb Fundamentals Summary
|BMY fundamental statistics|
Is BMY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BMY income statement (TTM)|
|Cost of Revenue||US$9.22b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 04, 2022
|Earnings per share (EPS)||-2.44|
|Net Profit Margin||-11.89%|
How did BMY perform over the long term?See historical performance and comparison
3.6%Current Dividend Yield
Is Bristol-Myers Squibb undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMY ($54.64) is trading below our estimate of fair value ($216.38)
Significantly Below Fair Value: BMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: BMY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BMY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BMY is overvalued based on its PB Ratio (3.3x) compared to the US Pharmaceuticals industry average (2.7x).
How is Bristol-Myers Squibb forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: BMY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BMY's is expected to become profitable in the next 3 years.
Revenue vs Market: BMY's revenue (2.2% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: BMY's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMY's Return on Equity is forecast to be very high in 3 years time (48.5%).
How has Bristol-Myers Squibb performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMY is currently unprofitable.
Growing Profit Margin: BMY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BMY is unprofitable, and losses have increased over the past 5 years at a rate of 52.1% per year.
Accelerating Growth: Unable to compare BMY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: BMY has a negative Return on Equity (-14.44%), as it is currently unprofitable.
How is Bristol-Myers Squibb's financial position?
Financial Position Analysis
Short Term Liabilities: BMY's short term assets ($31.4B) exceed its short term liabilities ($21.5B).
Long Term Liabilities: BMY's short term assets ($31.4B) do not cover its long term liabilities ($52.1B).
Debt to Equity History and Analysis
Debt Level: BMY's net debt to equity ratio (77.6%) is considered high.
Reducing Debt: BMY's debt to equity ratio has increased from 43.2% to 120% over the past 5 years.
Debt Coverage: BMY's debt is well covered by operating cash flow (34.7%).
Interest Coverage: BMY's interest payments on its debt are well covered by EBIT (7x coverage).
What is Bristol-Myers Squibb current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BMY's dividend (3.59%) is higher than the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: BMY's dividend (3.59%) is in the top 25% of dividend payers in the US market (3.57%)
Stability and Growth of Payments
Stable Dividend: BMY's dividends per share have been stable in the past 10 years.
Growing Dividend: BMY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: BMY is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: BMY's dividends in 3 years are forecast to be well covered by earnings (27% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Giovanni Caforio (56 yo)
Dr. Giovanni Caforio, M.D., serves as the Chief Executive Officer at Bristol-Myers Squibb Belgium NV/SA. He serves as Member of Business Roundtable and Chief Executive Officer Roundtable on Cancer. Dr. Caf...
CEO Compensation Analysis
Compensation vs Market: Giovanni's total compensation ($USD20.15M) is above average for companies of similar size in the US market ($USD11.14M).
Compensation vs Earnings: Giovanni's compensation has increased whilst the company is unprofitable.
Experienced Management: BMY's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: BMY's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BMY insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bristol-Myers Squibb Company's employee growth, exchange listings and data sources
- Name: Bristol-Myers Squibb Company
- Ticker: BMY
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$121.281b
- Shares outstanding: 2.22b
- Website: https://www.bms.com
Number of Employees
- Bristol-Myers Squibb Company
- 430 East 29th Street
- 14th Floor
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 00:09|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.